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Background: Alzheimer’s disease (AD) is characterized by a characteris-
tic pattern of reductions in the cerebral metabolic rate for glucose (CMRgl).
We recently introduced use of an AD-Related Hypometabolism Overlap
Index to determine the percentage of previously characterized AD-related
hypometabolic brain voxels that are hypometabolic in an individual sub-
ject’s fluorodeoxyglucose positron emission tomography (FDG-PET) im-
age and help distinguish between probable AD patients, amnestic mild
cognitive impairment (MCI) patients and normal controls (NC). The ob-
jective of this study is to evaluate the ability of our proposed Overlap Index
to distinguish between probable AD patients, MCI patients who convert to
probable AD within the next 18 months (MCIc), MCI patients who have so
far remained stable (MCIs) and NC from the AD Neuroimaging Initiative
(ADNI). Methods: The Overlap Index was computed in 74 AD patients,
14 MCIc, 124 MCIs patients, and 82 NC as follows: First, statistical
parametric mapping (SPM5) was used to generate individual cerebral
hypometabolism z-score maps, comparing each person to a database of 82
NC. Next, the individual hypometabolism map was superimposed on an
AD-related hypometabolic map generated from a previous study (Alex-
ander et al, 2002). Finally, the Overlap Index was computed as VADI/
VAD100%, such that VADI is the hypometabolic volume in both previous
AD-NC group comparison and the subsequent individual-NC comparison,
and VAD is the hypometabolic volume in only the previous AD-NC group
comparison. Results: The Overlap Index significantly distinguished the
four subject groups (ANOVA P8.8e-15). As predicted, the overlap index
had the following rank order: ADMCIcMCIsNC (ANOVA with
linear trend P3.9e-16). Moreover, the Overlap Index significantly distin-
guished between the MCIc group and the MCIs group (t-test P0.013).
Conclusions: Our preliminary findings suggest that the AD Overlap Index
can help identify hypometabolic patterns consistent with AD and help
differentiate MCI patients converting to AD from stable MCI patients
without the need to correct for multiple comparisons.
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Background: We previously used exploratory analyses to determine that
clinically mild Alzheimer’s disease (AD) is reliably associated with a “cortical
signature” of thinning in a specific set of regions in medial (MTL), inferior
(ITG), and polar temporal (TP), inferior, superior (SPL), and medial parietal,
and inferior and superior frontal cortices. We sought to determine whether the
pattern of AD-related thinning is present in individuals with questionable
dementia of the Alzheimer type (QAD) prior to mild AD and whether a greater
degree of regional thinning predicts mild AD dementia. Methods: Participants
included 49 older adults with QAD (Clinical Dementia Rating (CDR)0.5) at
the time of structural MRI scanning. Nine regions of interest (ROIs) identified
from an exploratory analysis comparing a separate sample of Older Controls
to mild AD (CDR1) patients were used to measure AD signature cortical
thickness in these participants. We also measured “mean AD signature” thick-
ness across all 9 regions. In addition, mean thickness across the entire cortex,
and whole brain, hippocampal and entorhinal volumes were calculated. Lon-
gitudinal clinical follow-up after scanning was used to classify participants as
progressors to CDR1 or non-progressors. Results: Longitudinal follow-up
revealed that 20 participants converted to mild AD dementia after approxi-
mately 2.5 years. At baseline, these QADs showed milder thinning in the
cortical ROIs as well as milder hippocampal and entorhinal atrophy than is
typically seen in mild AD. Compared to the non-progressors, the progressors
showed thinning in MTL, ITG, TP and SPL. Effect sizes for group differences
were higher for many regional thickness as compared to volume measures.
Using receiver operating characteristic curves, mean AD signature cortical
thickness was the best at predicting progression to mild AD with 83% sensi-
tivity and 65% specificity as compared to entorhinal volume, which achieved
72% sensitivity and 65% specificity. Conclusions: Thinning in specific cor-
tical areas known to be affected by AD is detectable in individuals with QAD
and predicts conversion to mild AD dementia. This method could be useful for
identifying individuals at relatively high risk for progression from QAD to
mild AD dementia within a few years, which may be of use in clinical trials.
IC-P2-076 WHITE MATTER VOLUME IN INDIVIDUALS AT
INCREASED RISK FOR ALZHEIMER’S DISEASE
C.E. Beauregard, Catherine Cristinzio, Guillermo Verduzco,
Susan Spear Bassett, Johns Hopkins School of Medicine, Baltimore, MD,
USA. Contact e-mail: ccristinzio@hotmail.com
Background: While much of structural imaging has focused on gray matter,
the quantification of white matter integrity is of interest not only because of the
noted white matter pathology seen in Alzheimer’s disease (AD), but also
because of the apparent breakdown of myelin in AD. To date there has been
no longitudinal study of white matter integrity within asymptomatic samples at
elevated risk for late-onset AD, the purpose of this study. Methods: Cogni-
tively normal participants age 50 years and above were chosen from an
ongoing longitudinal study, comparing those with increased genetic risk for
AD to matched controls. 95 of the high-risk and 91 of the controls had
structural scans at baseline (Time 1) and 87 high-risk and 74 controls at
three-year follow-up (Time 2). Participants were imaged at each time point on
the same 1.5 Tesla Philips Intera-NT system equipped with Galaxy gradients
(66mT/m at 110 mT/m/s). High resolution anatomical images of the brain for
structural measurements were acquired using a T1-weighted, 3D MP-RAGE
(Magnetization Prepared Rapid Acquisition Gradient Echo) sequence with the
following parameters: TR8.6 ms, TE3.9 ms, FOV240 mm, 8o, matrix
size 256x256, slice thickness1.5 mm, 124 slices). Pre-processing was
performed using a semi-automated method, followed by the manual removal
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